Doxorubicin chemotherapy for presumptive cardiac hemangiosarcoma in dogs † .

Autor: Mullin CM; The Oncology Service, Washington, DC, USA.; Red Bank Veterinary Hospital, Tinton Falls, NJ, USA., Arkans MA; Red Bank Veterinary Hospital, Tinton Falls, NJ, USA.; North Carolina State University, Raleigh, NC, USA., Sammarco CD; Red Bank Veterinary Hospital, Tinton Falls, NJ, USA., Vail DM; University of Wisconsin School of Veterinary Medicine, Madison, WI, USA., Britton BM; Red Bank Veterinary Hospital, Tinton Falls, NJ, USA.; BluePearl Veterinary Partners, New York, NY, USA., Vickery KR; Red Bank Veterinary Hospital, Tinton Falls, NJ, USA.; Hope Veterinary Specialists, Malvern, PA, USA., Risbon RE; Red Bank Veterinary Hospital, Tinton Falls, NJ, USA.; Veterinary Specialty & Emergency Center, Levittown, PA, USA., Lachowicz J; Red Bank Veterinary Hospital, Tinton Falls, NJ, USA.; BluePearl Veterinary Partners, New York, NY, USA., Burgess KE; Red Bank Veterinary Hospital, Tinton Falls, NJ, USA.; Tufts Cummings School of Veterinary Medicine, North Grafton, MA, USA., Manley CA; The Oncology Service, Washington, DC, USA.; Red Bank Veterinary Hospital, Tinton Falls, NJ, USA., Clifford CA; Red Bank Veterinary Hospital, Tinton Falls, NJ, USA.; Hope Veterinary Specialists, Malvern, PA, USA.
Jazyk: angličtina
Zdroj: Veterinary and comparative oncology [Vet Comp Oncol] 2016 Dec; Vol. 14 (4), pp. e171-e183. Date of Electronic Publication: 2014 Dec 18.
DOI: 10.1111/vco.12131
Abstrakt: Sixty-four dogs were treated with single-agent doxorubicin (DOX) for presumptive cardiac hemangiosarcoma (cHSA). The objective response rate (CR + PR) was 41%, and the biologic response rate (CR + PR + SD), or clinical benefit, was 68%. The median progression-free survival (PFS) for treated dogs was 66 days. The median survival time (MST) for this group was 116 days and was significantly improved compared to a MST of 12 days for untreated control dogs (P = 0.0001). Biologic response was significantly associated with improved PFS (P < 0.0001) and OS (P < 0.0001). Univariate analysis identified larger tumour size as a variable negatively associated with PFS. The high rate of clinical benefit and improved MST suggest that DOX has activity in canine cHSA.
(© 2014 John Wiley & Sons Ltd.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje